Bayer Submits SNDA For Expanded Use Of NUBEQA In Metastatic Hormone-Sensitive Prostate Cancer To FDA

RTTNews | 161天前
Bayer Submits SNDA For Expanded Use Of NUBEQA In Metastatic Hormone-Sensitive Prostate Cancer To FDA

(RTTNews) - German pharmaceutical company Bayer AG (BAYZF.PK, BAYRY.PK, BYR.L) announced Thursday the submission of a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for the oral androgen receptor inhibitor (ARi) NUBEQA (darolutamide) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC).

The submission is based on positive results from the investigational pivotal Phase III ARANOTE trial that showed NUBEQA plus ADT demonstrated an improvement in radiological progression-free survival (rPFS), significantly reducing in the risk of progression or death in patients with mHSPC compared to placebo plus ADT.

NUBEQA is developed jointly by Bayer and Orion Corporation, a globally operating Finnish pharmaceutical company.

NUBEQA is currently indicated for the treatment of adult patients with mHSPC in combination with docetaxel and for non-metastatic castration-resistant prostate cancer (nmCRPC).

read more
Bayer Stock Up On Growth View Starting FY26, Despite Q4 Loss, Cautious FY25

Bayer Stock Up On Growth View Starting FY26, Despite Q4 Loss, Cautious FY25

Shares of Bayer AG were gaining around 6 percent in the German trading after the pharmaceutical and life sciences major Wednesday said it expects improved performance from 2026 onwards, despite reporting a slip to loss in its fourth quarter. The company also projects weak core earnings and nearly flat sales for fiscal 2025.
RTTNews | 1天前
Bayer Stock Slips On Q3 Loss, Cautious Outlook

Bayer Stock Slips On Q3 Loss, Cautious Outlook

Shares of Bayer AG were losing around 11 percent in the morning trading on Germany's XETRA after the pharmaceutical and life sciences major reported Tuesday loss in its third quarter and weak adjusted EBITDA, amid nearly flat sales. The net loss, however, was narrower than last year, while EBIT loss widened. Further, the company trimmed its fiscal 2024 adjusted EBITDA forecast for the group...
RTTNews | 114天前
Bayer Stock Climbs On US Legal Win In Roundup Cancer Claims

Bayer Stock Climbs On US Legal Win In Roundup Cancer Claims

Shares of Bayer AG were climbing around 11 percent in German trading after the pharmaceutical and life sciences major announced a favorable ruling in the United States in the lawsuit over cancer claims against its Roundup weed killer. In a statement, the company noted that the Third Circuit Court of Appeals issued its favorable ruling in Schaffner v. Monsanto...
RTTNews | 202天前
Bayer Q4 Profit Surges, Warns On FY24; Says Break-up Not Now

Bayer Q4 Profit Surges, Warns On FY24; Says Break-up Not Now

German pharmaceutical and biotechnology major Bayer AG reported Tuesday a surge in its fourth-quarter net profit benefited by weak expenses. Meanwhile, sales were hurt by lower Pharmaceuticals sales, despite growth in Crop Science and consumer Health segments. Further, the company trimmed its dividend, and said it sees lower adjusted earnings and nearly flat sales in fiscal 2024 on a currency-adju
RTTNews | 366天前
Bayer's Mirena Gets Approval In Europe For Extended Duration Of Use In Contraception

Bayer's Mirena Gets Approval In Europe For Extended Duration Of Use In Contraception

German pharmaceutical company Bayer AG (BAYZF.PK, BAYRY.PK, BYR.L) announced Friday that Mirena (52mg LNG IUS), its long-acting reversible intrauterine system, received regulatory approval in the European Workshare Procedure for up to eight years in contraception. This is the longest contraceptive duration of use for any hormonal intrauterine system.
RTTNews | 874天前
Eurozone Retail Sales Fall Unexpectedly

Eurozone Retail Sales Fall Unexpectedly

Eurozone retail sales declined unexpectedly in January on non-food and auto fuel sales, official data showed on Thursday. Retail sales registered a monthly drop of 0.3 percent, confounding expectations for an increase of 0.1 percent. The statistical office revised up retail sales for December to nil growth from the initial estimate of 0.2 percent fall.
RTTNews | 5小时4分钟前
Turkey Central Bank Slashes Rate By 250 Bps

Turkey Central Bank Slashes Rate By 250 Bps

Turkey's central bank lowered its benchmark rate for the third straight time on Thursday as the underlying trend of inflation softened. The Monetary Policy Committee, headed by Yasar Fatih Karahan, decided to reduce the policy rate to 42.5 percent from 45.0 percent, as widely expected. The bank had reduced the rate by 250 basis points each in December and January.
RTTNews | 5小时43分钟前
Air France-KLM Stock Climbs On Narrower Q4 Loss, Positive Outlook

Air France-KLM Stock Climbs On Narrower Q4 Loss, Positive Outlook

Shares of Air France-KLM Group were gaining more than 20 percent in the morning trade in Paris after the airline reported Thursday narrower net loss and significantly higher EBITDA, a key earnings metric, in its fourth quarter amid good growth in passenger traffic, capacity and load factor. Further, the company projects capacity growth in fiscal 2025, and maintained medium term outlook.
RTTNews | 6小时30分钟前